Literature DB >> 14735241

[Primary sclerosing cholangitis].

A Stiehl1.   

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, characterized by fibrosing inflammation and obliteration of intra and/or extrahepatic bile ducts. The disease belongs to the most common cholestatic diseases in adults and at present is diagnosed with increasing frequency. It is very often associated with ulcerative colitis. Patients with PSC have an increased incidence of bile duct carcinomas and those with ulcerative colitis also have an increased incidence of colonic carcinomas. Immunosuppressive treatment is little effective. Ursodeoxycholic acid (UDCA) has been shown to improve liver histology in PSC. The aim is to treat patients as early as possible to prevent progression to the advanced stages of the disease. During treatment with UDCA stenoses of major ducts may develop and early endoscopic dilatation is highly effective. In patients with endstage disease, UDCA is not effective and liver transplantation is indicated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14735241     DOI: 10.1007/s00108-003-1116-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  32 in total

1.  Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC).

Authors:  Ulrika Broomé; Hans Glaumann; Eva Lindstöm; Lars Lööf; Sven Almer; Hanne Prytz; Hanna Sandberg-Gertzén; Stefan Lindgren; Frans-Thomas Fork; Gunnar Järnerot; Rolf Olsson
Journal:  J Hepatol       Date:  2002-05       Impact factor: 25.083

2.  Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.

Authors:  Darrell S Pardi; Edward V Loftus; Walter K Kremers; Jill Keach; Keith D Lindor
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

3.  Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series.

Authors:  C Schramm; P Schirmacher; I Helmreich-Becker; G Gerken; K H zum Büschenfelde; A W Lohse
Journal:  Ann Intern Med       Date:  1999-12-21       Impact factor: 25.391

4.  Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis.

Authors:  M Kaya; B T Petersen; P Angulo; T H Baron; J C Andrews; C J Gostout; K D Lindor
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

5.  Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography.

Authors:  S Keiding; S B Hansen; H H Rasmussen; A Gee; A Kruse; K Roelsgaard; U Tage-Jensen; J F Dahlerup
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

6.  Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.

Authors:  Adolf Stiehl; Gerda Rudolph; Petra Klöters-Plachky; Peter Sauer; Siegfried Walker
Journal:  J Hepatol       Date:  2002-02       Impact factor: 25.083

7.  Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential.

Authors:  U Broomé; R Löfberg; B Veress; L S Eriksson
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

8.  Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.

Authors:  A Stiehl; G Rudolph; P Sauer; L Theilmann
Journal:  J Hepatol       Date:  1995-09       Impact factor: 25.083

9.  Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis.

Authors:  R H Wiesner; P M Grambsch; E R Dickson; J Ludwig; R L MacCarty; E B Hunter; T R Fleming; L D Fisher; S J Beaver; N F LaRusso
Journal:  Hepatology       Date:  1989-10       Impact factor: 17.425

10.  Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Clinical and histologic response.

Authors:  M M Kaplan; S Arora; S H Pincus
Journal:  Ann Intern Med       Date:  1987-02       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.